Literature DB >> 9918682

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.

T L Wagner1, C L Ahonen, A M Couture, S J Gibson, R L Miller, R M Smith, M J Reiter, J P Vasilakos, M A Tomai.   

Abstract

Cytokines produced by antigen-presenting cells are known to affect the development and cytokine profile of T cells. The immune response modifiers imiquimod and R-848 were previously shown to stimulate human and mouse cultures to secrete interferon-alpha. Results from the present study demonstrate that R-848 and imiquimod are capable of inducing interleukin-12 and interferon-gamma in mouse and human cell cultures. Both CD4(+) and CD8(+) T lymphocytes were responsible for producing IFN-gamma following stimulation with R-848. Macrophages were required for induction of interferon-gamma by R-848 and the cytokines IFN-alpha and IL-12 mediated this response. R-848 and imiquimod were also found to inhibit IL-4 and IL-5 production in mouse and human culture systems. The inhibition of IL-5 in response to R-848 is seen in cultures containing CD4(+) lymphocytes and macrophages and is mediated in part by IFN-alpha. These data suggest that imiquimod and R-848 may have clinical utility in diseases where cell-mediated immune responses are important and in diseases associated with overexpression of IL-4 or IL-5 such as atopic disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918682     DOI: 10.1006/cimm.1998.1406

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  55 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

Authors:  Yong-yi Wang; Sha Liu; Feng Lian; Wen-gang Yang; Song Xue
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

3.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

4.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

5.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

6.  Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.

Authors:  Kenneth H Fife; Tze-Chiang Meng; Daron G Ferris; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

Review 7.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

8.  Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.

Authors:  Timothy W Schacker; Marcus Conant; Christopher Thoming; Tamara Stanczak; Zengri Wang; Michael Smith
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

Authors:  J Moisan; W Wojciechowski; C Guilbault; C Lachance; S Di Marco; E Skamene; G Matlashewski; D Radzioch
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

Authors:  Susan J Huang; Dirkjan Hijnen; George F Murphy; Thomas S Kupper; Adam W Calarese; Ilse G Mollet; Carl F Schanbacher; Danielle M Miller; Chrysalyne D Schmults; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.